Teens who frequently see billboard or storefront advertising for recreational cannabis products are more likely to use the drug weekly and to have symptoms of cannabis use disorder, according to new research.
A new trial has directly compared the antidepressant effects of psilocybin with a more classical antidepressant, and found that the two are matched in their mood-altering potential.
According to the study, up to a third of supposedly CBD-dominant cannabis products sold in Massachusetts may not contain any CBD at all.
Drug developers say that R-ketamine could potentially deliver a more targeted action with fewer side effects than its more popular chemical twin.
Blood tests are inherently flawed, research has shown, because they don’t indicate how long the THC has been in the system, the driver’s tolerance, how high they actually are or whether they are impaired at that moment.
Cannabis smokers experience emphysema at higher rates than both non-smokers and tobacco smokers, according to new research from the Ottawa Hospital.
This “small but significant increase” in fatal motor vehicle accidents and fatalities could be curbed by effective regulations and educational campaigns, according to researchers.
AOAC International is now inviting submissions from cannabis laboratories with unique methods for mycotoxin screening and for the detection of Shiga toxin-producing Escherichia coli in cannabis plant materials and derivatives.